Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vitae Pharmaceuticals LLC maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This action is situated within 1 distinct art unit, reflecting a focused area of examination for the company's active intellectual property. This suggests that the company's current legal activity is concentrated on a specific pharmaceutical or biotechnological advancement rather than a broad range of products.
The prosecution is handled by 1 distinct examiner, SEITZ, ANTHONY JOSEPH. As the busiest examiner, SEITZ, ANTHONY JOSEPH is responsible for 1 busiest examiner pending action. This single examiner manages the entire current pending workload, making their specific examination history a primary factor in the company's immediate prosecution strategy. Because all active prosecution is funneled through one individual, the company's ability to secure patent rights at this time is directly linked to the interactions with this specific examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289970 | INHIBITORS OF THE MENIN-MLL INTERACTION | SEITZ, ANTHONY JOSEPH | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289970 | INHIBITORS OF THE MENIN-MLL INTERACTION | SEITZ, ANTHONY JOSEPH | 1629 | DP | Final Rejection | 9d overdue | Pending | Nov 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial